• レポートコード:D0JU09097 • 出版社/出版日:Transparency Market Research / 2020年3月11日 • レポート形態:英文、PDF、251ページ • 納品方法:Eメール • 産業分類:製薬 |
Single User | ¥857,660 (USD5,795) | ▷ お問い合わせ |
Multi User | ¥1,301,660 (USD8,795) | ▷ お問い合わせ |
Corporate License | ¥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、神経障害薬の世界市場について調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、障害別(てんかん、アルツハイマー病、パーキンソン病、多発性硬化症、脳血管疾患、その他)分析、薬物クラス別(抗コリン作用薬、抗てんかん薬、抗精神病薬、催眠薬、鎮静薬、鎮痛薬、降圧薬、抗凝固薬、その他分析、流通経路別(小売薬局、病院薬局、オンライン薬局)分析、地域別分析、競争状況などの構成でお届けいたします。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場動向 ・市場概要 ・キーインサイト ・神経障害薬の世界市場:障害別(てんかん、アルツハイマー病、パーキンソン病、多発性硬化症、脳血管疾患、その他) ・神経障害薬の世界市場:薬物クラス別(抗コリン作用薬、抗てんかん薬、抗精神病薬、催眠薬、鎮静薬、鎮痛薬、降圧薬、抗凝固薬、その他 ・神経障害薬の世界市場:流通経路別(小売薬局、病院薬局、オンライン薬局) ・神経障害薬の世界市場:地域別 ・競争状況 |
Neurological Disorder Drugs Market – Scope of the Report
TMR’s report on the global neurological disorder drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2019 to 2027. The report provides the revenue of the global neurological disorder drugs market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global neurological disorder drugs market from 2019 to 2027.
The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global neurological disorder drugs market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various attributes of the global neurological disorder drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Moreover, the report sheds light on changing competitive dynamics in the global neurological disorder drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global neurological disorder drugs market.
The report also delves into the competitive landscape of the global neurological disorder drugs market. Key players operating in the global neurological disorder drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global neurological disorder drugs market that have been profiled in this report.
Key Questions Answered in Neurological Disorder Drugs Market Report
What is the sales/revenue generated by neurological disorder drugs across all regions during the forecast period?
What are the opportunities in the global neurological disorder drugs market?
What are the major drivers, restraints, opportunities, and threats in the global market?
Which region is set to expand at the fastest CAGR during the forecast period?
Which disorder segment is expected to generate the highest revenue globally in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Neurological Disorder Drugs Market – Research Objectives and Research Approach
The comprehensive report on the global neurological disorder drugs market begins with an overview, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that have been appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global neurological disorder drugs market in terms of disorder, drug class, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2027 has been provided. Such valuable insights enable market stakeholders to make informed business decisions for investment in the global neurological disorder drugs market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Neurological Disorder Drugs Market
4. Market Overview
4.1. Introduction & Overview
4.2. Product Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Neurological Disorder Drugs Market Analysis and Forecast, 2017–2027
5. Market Outlook
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate globally with key countries
5.3. Regulatory Scenario
6. Global Neurological Disorder Drugs Market Analysis and Forecast, by Disorder
6.1. Introduction & Definition
6.2. Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027
6.2.1. Epilepsy
6.2.2. Alzheimer Disease
6.2.3. Multiple Sclerosis
6.2.4. Parkinson Disease
6.2.5. Cerebrovascular Diseases
6.2.6. Others
6.3. Global Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder
7. Global Neurological Disorder Drugs Market Analysis and Forecast, by Drug Class
7.1. Introduction & Definition
7.2. Global Neurological Disorder Drugs Market Value (US$) Forecast, by Drug Class, 2017–2027
7.2.1. Anticholinergic
7.2.2. Antiepileptic
7.2.3. Antipsychotic
7.2.4. Analgesic
7.2.5. Hypnotic & Sedative
7.2.6. Antihypertensive
7.2.7. Anticoagulants
7.2.8. Others
7.3. Global Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class
8. Global Neurological Disorder Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
8.3. Global Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel
9. Global Neurological Disorder Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Neurological Disorder Drugs Market Attractiveness Analysis, by Region
10. North America Neurological Disorder Drugs Market Analysis and Forecast
10.1. Introduction
10.2. North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027
10.2.1. Epilepsy
10.2.2. Alzheimer Disease
10.2.3. Multiple Sclerosis
10.2.4. Parkinson Disease
10.2.5. Cerebrovascular Diseases
10.2.6. Others
10.3. North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
10.3.1. Anticholinergic
10.3.2. Antiepileptic
10.3.3. Antipsychotic
10.3.4. Analgesic
10.3.5. Hypnotic & Sedative
10.3.6. Antihypertensive
10.3.7. Anticoagulants
10.3.8. Others
10.4. North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
10.5.1. U.S.
10.5.2. Canada
10.6. North America Neurological Disorder Drugs Market Attractiveness Analysis
10.6.1. By Disorder
10.6.2. By Drug Class
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Neurological Disorder Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027
11.2.1. Epilepsy
11.2.2. Alzheimer Disease
11.2.3. Multiple Sclerosis
11.2.4. Parkinson Disease
11.2.5. Cerebrovascular Diseases
11.2.6. Others
11.3. Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
11.3.1. Anticholinergic
11.3.2. Antiepileptic
11.3.3. Antipsychotic
11.3.4. Analgesic
11.3.5. Hypnotic & Sedative
11.3.6. Antihypertensive
11.3.7. Anticoagulants
11.3.8. Others
11.4. Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Neurological Disorder Drugs Market Attractiveness Analysis
11.6.1. By Disorder
11.6.2. By Drug Class
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Neurological Disorder Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027
12.2.1. Epilepsy
12.2.2. Alzheimer Disease
12.2.3. Multiple Sclerosis
12.2.4. Parkinson Disease
12.2.5. Cerebrovascular Diseases
12.2.6. Others
12.3. Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
12.3.1. Anticholinergic
12.3.2. Antiepileptic
12.3.3. Antipsychotic
12.3.4. Analgesic
12.3.5. Hypnotic & Sedative
12.3.6. Antihypertensive
12.3.7. Anticoagulants
12.3.8. Others
12.4. Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Neurological Disorder Drugs Market Attractiveness Analysis
12.6.1. By Disorder
12.6.2. By Drug Class
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Neurological Disorder Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027
13.2.1. Epilepsy
13.2.2. Alzheimer Disease
13.2.3. Multiple Sclerosis
13.2.4. Parkinson Disease
13.2.5. Cerebrovascular Diseases
13.2.6. Others
13.3. Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
13.3.1. Anticholinergic
13.3.2. Antiepileptic
13.3.3. Antipsychotic
13.3.4. Analgesic
13.3.5. Hypnotic & Sedative
13.3.6. Antihypertensive
13.3.7. Anticoagulants
13.3.8. Others
13.4. Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Neurological Disorder Drugs Market Attractiveness Analysis
13.6.1. By Disorder
13.6.2. By Drug Class
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Neurological Disorder Drugs Market Analysis and Forecast
14.1. Introduction
14.2. Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027
14.2.1. Epilepsy
14.2.2. Alzheimer Disease
14.2.3. Multiple Sclerosis
14.2.4. Parkinson Disease
14.2.5. Cerebrovascular Diseases
14.2.6. Others
14.3. Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
14.3.1. Anticholinergic
14.3.2. Antiepileptic
14.3.3. Antipsychotic
14.3.4. Analgesic
14.3.5. Hypnotic & Sedative
14.3.6. Antihypertensive
14.3.7. Anticoagulants
14.3.8. Others
14.4. Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Neurological Disorder Drugs Market Attractiveness Analysis
14.6.1. By Disorder
14.6.2. By Drug Class
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Competition Matrix
15.2. Market Share Analysis, by Company, 2018
15.3. Company Profiles
15.3.1. Novartis AG
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Company Financials
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.3.2. GlaxoSmithKline plc
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Company Financials
15.3.2.3. Growth Strategies
15.3.2.4. SWOT Analysis
15.3.3. F. Hoffmann-La Roche Ltd.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Company Financials
15.3.3.3. Growth Strategies
15.3.3.4. SWOT Analysis
15.3.4. Pfizer, Inc.
15.3.4.1. Company Overview (HQ, Business Segments)
15.3.4.2. Company Financials
15.3.4.3. Growth Strategies
15.3.4.4. SWOT Analysis
15.3.5. Bayer AG
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Company Financials
15.3.5.3. Growth Strategies
15.3.5.4. SWOT Analysis
15.3.6. Boehringer Ingelheim International GmbH
15.3.6.1. Company Overview (HQ, Business Segments)
15.3.6.2. Company Financials
15.3.6.3. Growth Strategies
15.3.6.4. SWOT Analysis
15.3.7. AstraZeneca plc
15.3.7.1. Company Overview (HQ, Business Segments)
15.3.7.2. Company Financials
15.3.7.3. Growth Strategies
15.3.7.4. SWOT Analysis
15.3.8. Teva Pharmaceutical Industries Ltd.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Company Financials
15.3.8.3. Growth Strategies
15.3.8.4. SWOT Analysis
15.3.9. Merck & Co., Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Company Financials
15.3.9.3. Growth Strategies
15.3.9.4. SWOT Analysis
15.3.10. Otsuka Pharmaceutical Co., Ltd.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Company Financials
15.3.10.3. Growth Strategies
15.3.10.4. SWOT Analysis
15.3.11. Amgen, Inc.
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Company Financials
15.3.11.3. Growth Strategies
15.3.11.4. SWOT Analysis
15.3.12. UCB S.A.
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Company Financials
15.3.12.3. Growth Strategies
15.3.12.4. SWOT Analysis
15.3.13. Eli Lilly and Company
15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.13.2. Company Financials
15.3.13.3. Growth Strategies
15.3.13.4. SWOT Analysis
15.3.14. Biogen
15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.14.2. Company Financials
15.3.14.3. Growth Strategies
15.3.14.4. SWOT Analysis
List of TablesTable 01: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027
Table 02: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 03: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 04: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 05: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027
Table 06: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 07: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 08: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 09: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027
Table 10: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 11: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 12: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 13: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027
Table 14: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 15: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 16: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 17: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027
Table 18: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 19: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 20: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 21: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027
Table 22: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 23: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 24: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027